Oligonucleotide array-based comparative genomic hybridization (aCGH) of 90 neuroblastomas reveals aberration patterns closely associated with relapse pattern and outcome

Genes Chromosomes and Cancer

Volumn 45, Issue 12, 2006, Pages 1130-1142

  Spitz, Ruediger ^a,c   Oberthuer, Andre ^a   Zapatka, Marc ^b   Brors, Benedikt ^b   Hero, Barbara ^a   Ernestus, Karen ^a   Oestreich, Joern ^a   Fischer, Matthias ^a   Simon, Thorsten ^a   Berthold, Frank ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CHROMOSOME 1; CHROMOSOME 11; CHROMOSOME 11Q; CHROMOSOME 12Q; CHROMOSOME 14; CHROMOSOME 17; CHROMOSOME 17Q; CHROMOSOME 1P; CHROMOSOME 21Q; CHROMOSOME 2P; CHROMOSOME 3; CHROMOSOME 3P; CHROMOSOME 4; CHROMOSOME 6Q; CHROMOSOME 7; CHROMOSOME ABERRATION; CHROMOSOME BREAKAGE; CHROMOSOME DELETION; CHROMOSOME LOSS; CHROMOSOME MAP; COHORT ANALYSIS; COMPARATIVE GENOMIC HYBRIDIZATION; CYTOGENETICS; DNA MICROARRAY; GENE AMPLIFICATION; GENE DELETION; GENE SEQUENCE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; NEUROBLASTOMA; NUCLEOTIDE SEQUENCE; ONCOGENE MYC; PHENOTYPE; PRIORITY JOURNAL; X CHROMOSOME;

CHROMOSOME ABERRATIONS; CHROMOSOME BREAKAGE; CHROMOSOME MAPPING; COHORT STUDIES; GENE AMPLIFICATION; GENOME, HUMAN; HUMANS; NEUROBLASTOMA; NUCLEIC ACID HYBRIDIZATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; RECURRENCE;

EID: 33751092280     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20376     Document Type: Article

References (33)

1. Attiyeh EF, London WB, Mosse YP, Wang Q, Winter C, Khazi D, McGrady PW, Seeger RC, Look AT, Shimada II, Brodeur GM, Cohn SL, Matthay KK, Maris JM. 2005. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 353:2243-2253.
2. Barrett MT, Scheffer A, Ben-Dor A, Sampas N, Lipson D, Kincaid R, Tsang P, Curry B, Baird K, Meltzer PS, Yakhini Z, Bruhn L, Laderman S. 2004. Comparative genomic hybridization using oligonucleotide microarrays and total genomic DNA. Proc Natl Acad Sci USA 101:17765-17770.
3. Beheshti B, Braude I, Marrano P, Thorner P, Zielenska M, Squire JA. 2003. Chromosomal localization of DNA amplifications in neuroblastoma tumors using cDNA microarray comparative genomic hybridisation. Neoplasia 5:53-62.
4. Bilke S, Chen QR, Westermann K, Schwab M, Catchpoole D, Khan J. 2005. Inferring a tumor progression model for neuroblastoma from genomic data. J Clin Oncol 23:7322-7331.
5. Brinkschmidt C, Christiansen H, Terpe HJ, Simon R, Boecker W, Lampert F, Stoerkel S. 1997. Comparative genomic hybridization (CGH) analysis of neuroblastomas-an important methodological approach in paediatric tumour pathology. J Pathol 181:394-400.
6. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, De Bernardi B, Evans AE, Fayrot M, Hedborg F, Kaneko M, Kemshead J, Lamport F, Lee REJ, Look AT, Pearson ADJ, Philip T, Roald B, Sawada T, Seeger RC, Tsuchida V, Voute PA. 1993. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11:1466-1477.
7. Chen QR, Bilke S, Wei JS, Whiteford CC, Cenacchi N, Krasnoselsky Al, Greer BT, Son CG, Westermann F, Berthold F, Schwab M, Catchpoole D, Khan J. 2004. cDNA array-CGH profiling identifies genomic alterations specific to stage and MYCN-amplification in neuroblastoma. BMC Genomics 5:70.
8. De Preter K, Speleman F, Combaret V, Lunee J, Laureys G, Eussen BHJ, Francotte N, Board J, Person ADJ, De Paepe A, Van Roy N, Vandesompele J. 2002. Quantification of MYCN, DDX1, and NAG gene copy number in neuroblastoma using a real-time quantitative PCR assay. Mod Pathol 15:159-166.
9. De Preter K, Vandesompele J, Menten B, Carr P, Fiegler H, Edsjo A, Carter NP, Yigit N, Waelput W, Van Roy N, Bader S, Pahlman S, Speleman F. 2005. Positional and functional mapping of a neuroblastoma differentiation gene on chromosome 11. BMC Genomics 6:97.
10. Guo C, White PS, Weiss MJ, Hogarty MD, Thompson PM, Stram DO, Gerbing R, Matthay KK, Seeger RC, Brodeur GM, Maris JM. 1999. Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas. Oncogene 18:4948-4957.
11. Iehara T, Hamazaki M, Sawada T. 2002. Cytogenetic analysis of infantile neuroblastomas by comparative genomic hybridization. Cancer Lett 178:83-89.
12. Jones TA, Flomen RH, Senger G, Nizetic D, Sheer D. 2000. The homeobox gene MEIS1 is amplified in IMR-32 and highly expressed in other neuroblastoma cell lines. Eur J Cancer 36:2368-2374.
13. Kallioniemi A, Kallioniemi OP, Sudar D, Rutovitz D, Gray JW, Waldman F, Pinkel D. 1992. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 258:818-821.
14. Lastowska M, Nacheva E, McGuckin A, Curtis A, Grace C, Pearson A, Bown N. 1997. Comparative genomic hybridization study of primary neuroblastoma tumors. United Kingdom Children's Cancer Study Group. Genes Chromosomes Cancer 18:162-169.
15. Lastowska M, Cotterill S, Bown N, Cullinane C, Variend S, Lunee J, Strachan T, Pearson AD, Jackson MS. 2002. Breakpoint position on 17q identifies the most aggressive neuroblastoma tumors. Genes Chromosomes Cancer 34:428-436.
16. Mosse YP, Greshock J, Margolin A, Naylor T, Cole K, Khazi D, Hii G, Winter C, Shahzad S, Asziz MU, Biegel JA, Weber BL, Maris JM. 2005. High-resolution detection and mapping of genomic DNA alterations in neuroblastoma. Genes Chromosomes Cancer 43:390-403.
17. Oberthuer A, Skowron M, Spitz, R, Kahlett Y, Westermann F, Mehler K, Berthold F, Fischer M. 2005. Characterization of a complex genomic alteration on chromosome 2p that leads to four alternatively spliced fusion transcripts in neuroblastoma cell lines IMR-5, IMR5/75 and IMR32. Gene 19:41-50.
18. Pinkel D, Segraves R, Sudar D, Clark S, Poole I, Kowbel D, Collins C, Kuo WL, Chen C, Zhai Y, Dairkee SH, Ljung BM, Gray JW, Albertson DG. 1998. High resolution analysis of DNA copy number variation using comparative genomic hybridisation to microarrays. Nat Genet 20:207-211.
19. Plantaz D, Vandesompele J, Van Roy N, Lastowska M, Bown N, Combaret V, Favrot MC, Delattre O, Michon J, Benard J, Hartmann O, Nicholson JC, Ross FM, Brinkschmidt C, Laureys G, Caron H, Matthay KK, Feuerstein BG, Speleman F. 2001. Comparative genomic hybridization (GGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplification. Int J Cancer 91:680-686.
20. Pollack JR, Perou CM, Alizadeh AA, Eisen MB, Pergamenschikov A, Williams CF, Jeffrey SS, Botstein D, Brown PO. 1999. Genome-wide analysis of DNA copy-number changes using cDNA microarrays. Nat Genet 23:41-46.
21. Schwab M, Westermann F, Hero B, Berthold F. 2003. Neuroblastoma: Biology and molecular and chromosomal pathology. Lancet Oncol 4:472-480.
22. Selzer RR, Richmond TA, Pofahl NJ, Green RD, Eis PS, Nair P, Brothman AR, Stallings RL. 2005. Analysis of chromosome break-points in neuroblastoma at sub-kilobase resolution using fine-tiling oligonucleotide array CGH. Genes Chromosomes Cancer 44:305-319.
23. Solinas-Toldo S, Lampel S, Stilgenbauer S, Nickolenko J, Benner A, Dohner H, Cremer T, Lichter P. 1997. Matrix-based comparative genomic hybridization: Biochips to screen for genomic imbalances. Genes Chromosomes Cancer 20:399-407.
24. Spieker N, van Sluis P, Beitsma M, Boon K, van Sehaik BD, van Kampen AH, Caron M, Versteeg R. 2001. The MEIS1 oncogene is highly expressed in neuroblastoma and amplified in cell line IMR32. Genomics 71:214-221.
25. Spitz R, Hero B, Ernestus K, Berthold F. 2003a. Deletions in chromosome arms 3p and 11q are new prognostic markers in localized and 4s neuroblastoma. Clin Cancer Res 9:52-58.
26. Spitz R, Hero B, Ernestus K, Berthold F. 2003b. Gain of distal chromosome arm 17q is not associated with poor prognosis in neuroblastoma. Clin Cancer Res 9:4835-4840.
27. Spitz R, Hero B, Skowron M, Ernestus K, Berthold F. 2004. MYCN-status in neuroblastoma: Characteristics of tumours showing amplification, gain, and non-amplification. Eur J Cancer 40:2753-2759.
28. Stallings RL, Nair P, Maris JM, Catchpoole D, McDermott M, O'Meara A, Breatnach F. 2006. High-resolution analysis of chromosomal break-points and genomic instability identifies PTPRD as a candidate tumor suppressor gene in neuroblastoma. Cancer Res 66:3673-3680.
29. Vandesompele J, Van Roy N, Van Gele M, Laureys G, Ambros P, Heimann P, Devalck C, Schuuring E, Brock P, Otten J, Gyselinck J, De Paepe A, Speleman F. 1998. Genetic heterogeneity of neuroblastoma studied by comparative genomic hybridization. Genes Chromosomes Cancer 23:141-152.
30. Vandesompele J, Speleman F, Van Roy N, Laureys G, Brinskchmidt C, Christiansen H, Lampert F, Lastowska M, Bown N, Pearson A, Nicholson JC, Ross F, Combaret V, Delattre O, Feuerstein BG, Plantaz D. 2001. Multicentre analysis of patterns of DNA gains and losses in 204 neuroblastoma tumors: How many genetic sub-groups are there? Med Pediatr Oncol 36:5-10.
31. Vettenranta K, Aalto Y, Wikstrom S, Knuutila S, Saarinen-Pihkala U. 2001. Comparative genomic hybridization reveals changes in DNA-copy number in poor-risk neuroblastoma. Cancer Genet Cytogenet 125:125-130.
32. Weber A, Imisch P, Bergmann E, Christiansen H. 2004. Coamplification of DDX1 correlates with an improved survival probability in children with MYCN-amplified human neuroblastoma. J Clin Oncol 22:2681-2690.
33. White PS, Thompson PM, Gotoh T, Okawa ER, Igarashi J, Kok M, Winter C, Gregory SG, Hogarty MD, Maris JM, Brodeur GM. 2005. Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma. Oncogene 24:2684-2694.